MolMed was an Italian biotechnology company specializing in the research, development, production, and clinical validation of cell and gene therapies, primarily targeting cancer and rare diseases. It initially operated as a contract manufacturing organization before developing its own products, including the cell therapy TK (Zalmoxis). The company was founded in 1996 in Milan, Italy.